US FDA approves three different oncology drugs in 1 week
In the last week, the US FDA has granted approval/accelerated approval to three different oncology drugs, each from different drugmakers with different indications.
Since February 17, 2024 to the time of this article’s publication, the US FDA have announced approvals for three different oncology drug products from three different drugmakers: AstraZeneca, Iovance Biotherapeutics, and Johnson & Johnson. The approvals are as follows:
AstraZeneca
The US FDA has granted approval to AstraZeneca’s Tagrisso in combination with chemotherapy for the treatment of stage 3 EGFR-mutated non-small cell lung cancer (NSCLC). Tagrisso acts a targeted tyrosine kinase inhibitor, and has demonstrated a significant reduction in the risk of disease progression or death. For EGFR-mutated NSCLC, Tagrisso is currently the only targeted therapy to improve patient outcomes in both early- and late-stage disease. The FDA’s approval came based on trials that extended progression-free survival of a median of 9 years.
Executive Vice President of the Oncology Business Unit at AstraZeneca Dave Fredrickson stated in a press release: “This important new treatment option can delay disease progression by nearly 9 additional months, establishing a new benchmark with the longest reported progression-free survival benefit in the 1st-line advanced setting. This approval reinforces Tagrisso as the backbone of EGFR-mutated lung cancer treatment either as monotherapy or in combination with chemotherapy.”
While the clinical data for Tagrisso’s efficacy in reducing disease progression still requires maturation, a global study to assess Tagrisso’s efficacy and safety in combination with chemoradiation for stage III unresectable NSCLC in a phase III trial is estimated to be fully complete by 2026.
Iovance Biotherapeutics
Iovance Biotherapeutics was also granted accelerated approval by the US FDA for a cell therapy treatment for advanced melanoma, the first of its kind to be approved for the indication and for a solid tumour cancer.
AMTAGVI, a suspension for intravenous infusion, is a T cell immunotherapy for adult patients presenting with unresectable/metastatic melanoma that has been previously treated with a PD-1 blocking antibody. With accelerated approval based on the overall response rate and duration of response, AMTAGVI is currently undergoin phase III trials to confirm clinical significance.
Samantha R. Guild, President, AIM at the Melanoma Foundation, commented in a press release: “The approval of AMTAGVI offers hope to those with advanced melanoma who have progressed following initial standard of care therapies, as the current treatment options are not effective for many patients... This one-time cell therapy represents a promising innovation for the melanoma community, and we are excited by its potential to transform care for patients who are in dire need of additional therapeutic options.”
Johnson & Johnson
A bi-weekly treatment for those presenting with relapsed or refractory multiple myeloma has also been granted approval by the US FDA. TECVAYLI was granted FDA approval of the supplemental Biologics License Application at a reduced dosing frequency of 1.5 mg/kg every 2 weeks.
TECVAYLI is the first bispecific antibody targeting B-cell maturation antigen (BCMA) on multiple myeloma cells and CD3 on T cells, activating an immune response. In October 2022, TECVAYLI was approved for the treatment of adult patients with relapse/refractory multiple myeloma that had already received at least four lines of therapy.
Rachel Kobos, VP, Oncology Research & Development at Johnson & Johnson, stated in a press release: “TECVAYLI is the only BCMA-targeted immune-based therapy with weight-based dosing. Today’s approval of bi-weekly dosing for eligible patients will further enable clinicians to meet the individual needs of patients who may want flexibility in their dosing schedules... As the first bispecific approved for the treatment of multiple myeloma, combined with the longest in-market experience by physicians, TECVAYLI is another example of our commitment to pioneering cutting-edge research to help improve outcomes for patients with multiple myeloma.”
Sources
[1] Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer [Accessed February 22, 2024] https://www.astrazeneca.com/media-centre/press-releases/2024/tagrisso-plus-chemo-approved-in-us-for-lung-cancer.html
[2] Iovance’s AMTAGVI (Iifileucel) receives US FDA Accelerated Approval for Advanced Melanoma [Accessed February 22, 2024] https://ir.iovance.com/news-releases/news-release-details/iovances-amtagvitm-lifileucel-receives-us-fda-accelerated
[3] TECVAYLI (teclistamab-cqyv) biweekly dosing approved by the US FDA for the treatment of patients with relapsed or refractory multiple myeloma [Accessed February 22, 2024] https://investor.jnj.com/files/doc_news/2024/Feb/20/tecvayli-biweekly-dosing-fda-approval-press-release_final.pdf
Related News
-
News What the Novo Holdings and Catalent deal means for pharma outsourcing
On February 5, 2024, Novo Holdings announced their intention to acquire pharma and biotech CDMO Catalent at US$16.5 billion. Read more about what this means for the pharmaceutical industry as a whole, from drugmakers to their partners in manufacturing.... -
News Key takeaways from Saudi Arabia's National Biotechnology Strategy
In January 2024, Saudi Arabia released its National Biotech Strategy, an ambitious plan to localise biomanufacturing, incentivise R&D and establish the Kingdom as the regional biotech leader by 2030, and an internationally recognised hub by 2040. -
News Novo Holdings buys CDMO Catalent in US$16.5 billion deal
Novo Nordisk’s holding and investment parent company will acquire the publicly owned CDMO at the end of 2024, taking it private and selling three of its drug manufacturing facilities to Novo Nordisk. -
News Special Edition Women in Pharma: International Day of Women and Girls in Science
In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. -
News Pharmapack Awards 2024 Start-up Innovation Award Winner – Capa Valve Ltd
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance